<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00372268</url>
  </required_header>
  <id_info>
    <org_study_id>3621</org_study_id>
    <nct_id>NCT00372268</nct_id>
  </id_info>
  <brief_title>Effects of Insufflated Gas on Core Temperature and Post-operative Pain During Laparoscopic Surgery</brief_title>
  <official_title>Evaluation of the Effects of Conditioning of Insufflated Gas on the Core Temperature and the Post-operative Pain During Laparoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During laparoscopy, administration of cold and dry carbon dioxide (CO2) leads to hypothermia.&#xD;
      Different types of gas conditioning have been studied in order to prevent this specific&#xD;
      hypothermia. Intra-abdominal administration of local anesthetics has also been studied in&#xD;
      order to prevent post-operative pain. In both cases, some results have been described.&#xD;
&#xD;
      The investigators propose to evaluate in a prospective, randomized, double blind trial, the&#xD;
      impact of 4 different types of conditioning of insufflated gas during laparoscopy for womb&#xD;
      surgery on hypothermia prevention and post-operative pain. These 4 types of gas conditioning&#xD;
      are:&#xD;
&#xD;
        -  CO2 wet and cold with nebulized Nacl and direct intra-abdominal administration of Nacl&#xD;
&#xD;
        -  CO2 wet and cold with nebulized ropivacaïne 0.75% and direct intra-abdominal&#xD;
           administration of Nacl&#xD;
&#xD;
        -  CO2 dry and cold with direct intra-abdominal administration of ropivacaïne 0.2%&#xD;
&#xD;
        -  CO2 dry and cold with direct intra-abdominal administration of Nacl&#xD;
&#xD;
      The investigators use a new device (Aeroneb® Pro [Aerogen® Company]) which can wet (by&#xD;
      nebulization) the insufflated gas and therefore permits intraperitoneal medicament&#xD;
      administration (local anesthetics).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of core temperature</measure>
    <time_frame>From the beginning of the anesthetic procedure to the discharge of the recovery room.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-operative pain</measure>
    <time_frame>From the arrival in the recovery room to the 6th post-operative day.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation parameters</measure>
    <time_frame>From the beginning of the anesthetic procedure to the end of the surgical procedure (one blood sample is done before the surgery, the second is done just after the arrival in the recovery room)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From the discharge of the recovery room to the 6th post-operative day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical comfort</measure>
    <time_frame>During the duration of the surgical procedure.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">248</enrollment>
  <condition>Laparoscopy</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Hypothermia</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of ropivacaïne 0,2% by direct intra-abdominal administration at the end of the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of ropivacaïne 0,75% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of Nacl 0,9% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of Nacl 0,9% by direct intra-abdominal administration at the end of the surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aeroneb® Pro (Nektar® Company)</intervention_name>
    <description>The Aeroneb® Pro (Nektar® Company) permits cold and wet nebulization of either saline solution or ropivacaïne 0.75% (Naropeine) during the surgical procedure.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aeroneb® Pro (Nektar® Company)</intervention_name>
    <description>The Aeroneb® Pro (Nektar® Company) permits cold and dry nebulization without saline solution neither ropivacaïne (Naropéine) during the surgical procedure.</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Womb surgery by laparoscopy&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Aged over 18 years&#xD;
&#xD;
          -  No emergency&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Laparotomy&#xD;
&#xD;
          -  Protocol rejected by the patient&#xD;
&#xD;
          -  Request of the surgeon or the anesthesiologist to know the administration solution or&#xD;
             the insufflated gas&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre DIEMUNSCH, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sihcus-Cmco</name>
      <address>
        <city>Schiltigheim</city>
        <zip>67300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Perioperative Medicine and Intensive Care - SAN GERARDO HOSPITAL</name>
      <address>
        <city>Monza</city>
        <zip>20051</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>September 5, 2006</study_first_submitted>
  <study_first_submitted_qc>September 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2006</study_first_posted>
  <last_update_submitted>April 12, 2012</last_update_submitted>
  <last_update_submitted_qc>April 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Comparison of four conditionings of the insufflated gas during laparoscopy and their consequences on the core temperature and the post-operative pain.</keyword>
  <keyword>Women with womb pathology needing laparoscopic surgery</keyword>
  <keyword>No emergency</keyword>
  <keyword>Aged over 18 years</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

